Genetics of Hyperuricemia Therapy in Hmong

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To pursue this objective, we will be measuring uric acid at baseline and post 14 days of twice daily allopurinol therapy in 30 Hmong participants with documented gout or hyperuricemia and known genotype for key renal transporters of uric acid.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• Both parents are Hmong (self report)

• Self report history of gout, or

• History (within one year) of active use of xanthine oxidase inhibitors, or

• Evidence of serum uric acid ≥ 6mg/dL , or

• Serum uric acid < 6mg/dL with history of ≥ 2 gout episodes within the last 6 months

• Ability to provide informed consent for participation in the study

• Demonstrate understanding of the study procedures and ability to comply with the study drug for the entire length of the study

• Ability to obtain permission from treating clinician to allow stopping the drug for 10 days

Exclusion Criteria:

• Pregnant women or women of childbearing age sexually active and not using any contraception

• estimated creatinine clearance (eCrCl) <30ml/min

• Elevated liver enzymes (3 x upper normal limit of liver function tests (AST and ALT))

• Contraindication to receiving allopurinol

• Active participation in other clinical trial (or within 30 days)